Insmed To Present at September Investor Conferences
INSMBRIDGEWATER, N.J., Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will...
Amber Specialty Pharmacy Begins Dispensing Newly Approved BRINSUPRI™ (brensocatib) for Non-Cystic Fibrosisbronchiectasis (NCFB)
INSMOMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing BRINSUPRI™ (brensocatib) following the medication’s U.S. Food and Drug Administration (FDA) approval as the first treatment specifically indicated to reduce pulmonary exacerbations in adults and adolescents with non-cystic fibrosis bronchiectasis, a chronic neutrophil-mediated airway disease. “Our nationally recognized clinical program is ready to
VytlOne Announces New Partnership with Insmed
INSMAMARILLO, Texas, Aug. 13, 2025 /PRNewswire/ -- Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis...
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
INSMPITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced that it was selected by Insmed as part of the network of specialty pharmacies to dispense BRINSUPRI™ (brensocatib), a...
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
INSM—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12,...
Reported Earlier, Insmed Prices $750M Public Offering Of 7,812,500 Shares At $96 Each
INSM$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
INSMInsmed Announces Proposed $650M Public Offering
INSMGoldman Sachs Maintains Buy on Insmed, Raises Price Target to $112
INSMInsmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
INSMBofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.
Mizuho Maintains Outperform on Insmed, Raises Price Target to $110
INSMRBC Capital Maintains Outperform on Insmed, Raises Price Target to $106
INSMMorgan Stanley Maintains Overweight on Insmed, Raises Price Target to $102
INSMB of A Securities Maintains Buy on Insmed, Raises Price Target to $109
INSMWells Fargo Maintains Overweight on Insmed, Raises Price Target to $119
INSMHC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $120
INSMDeep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings)
INSMInsmed's TPIP Demonstrates Statistically Significant 35% Reduction In Pulmonary Vascular Resistance And 35.5-Meter Improvement In Six-Minute Walk Distance In Phase 2 Study, Shows Sustained 24-Hour Benefits And Well Tolerated With 75% Patients Reaching Hig
INSMInsmed Announces Topline Results From Phase 2b Study Of Treprostinil Palmitil Inhalation Powder (TPIP) As Once-Daily Therapy In Patients With Pulmonary Arterial Hypertension
INSMIf You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
INSMHow Do Investors Really Feel About Insmed?
INSMInsmed Incorporated Announces It Presented 11 New Abstracts At The American Thoracic Society 2025 International Conference, Including Three Prespecified Subgroup Analyses From The Phase 3 Aspen Trial Of Brensocatib In Non-cystic Fibrosis Bronchiectasis
INSMJefferies Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $105
INSMAnalyst Expectations For Insmed's Future
INSMHC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
INSMUBS Maintains Buy on Insmed, Lowers Price Target to $109
INSM$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
INSMInsmed Affirms FY2025 Sales Guidance of $405.00M-$425.00M vs $467.80M Est
INSMInsmed Q1 EPS $(1.42) Misses $(1.33) Estimate, Sales $92.82M Beat $92.08M Estimate
INSMIs Insmed Gaining or Losing Market Support?
INSMIf You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
INSMInsmed Reveals Redemption Of All $569.5M Of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
INSMInsmed Announces New England Journal Of Medicine Publishes Results From Its Pivotal Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis; Largest Global Clinical Trial Ever Conducted In Bronchiectasis Demonstrates Statistically Significant A
INSMHC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
INSMHere's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
INSM$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
INSMB of A Securities Maintains Buy on Insmed, Raises Price Target to $96
INSMExpert Outlook: Insmed Through The Eyes Of 13 Analysts
INSMUBS Maintains Buy on Insmed, Raises Price Target to $110
INSMHere's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
INSMLung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
INSMRBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.
RBC Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $100
INSMGuggenheim Reiterates Buy on Insmed, Maintains $101 Price Target
INSMInsmed Announces FDA No Advisory Meeting For Brensocatib NDA In Non-Cystic Fibrosis Bronchiectasis
INSMHC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
INSMTruist Securities Maintains Buy on Insmed, Raises Price Target to $108
INSMStifel Maintains Buy on Insmed, Lowers Price Target to $96
INSMHC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target
INSMCantor Fitzgerald Reiterates Overweight on Insmedto Overweight
INSMInsmed shares are trading lower after the company reported Q4 financial results and missed its EPS estimate.
INSM